MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

42.96 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,282
Open 42.96
Bid (Size) 42.66 (300)
Ask (Size) 42.69 (1,400)
Prev. Close 42.96
Today's Range 42.96 - 42.96
52wk Range 35.12 - 81.44
Shares Outstanding N/A
Dividend Yield 5.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? ↗
Novo Nordisk could maintain this latest early-mover advantage longer than you think. 
Via The Motley Fool
News headline image
Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? ↗
Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake. 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
-18.0%
-18.0%
1 Month
-6.8%
-6.8%
3 Month
+8.0%
+8.0%
6 Month
-8.1%
-8.1%
1 Year
-43.1%
-43.1%

More News

Read More
News headline image
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors ↗
Via The Motley Fool
News headline image
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better ↗
Via The Motley Fool
News headline image
Here's What I Think Is Really Going on With Novo Nordisk Stock ↗
Via The Motley Fool
News headline image
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗
Via The Motley Fool
News headline image
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage ↗
Via MarketBeat
News headline image
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗
Via The Motley Fool
News headline image
Lexicon (LXRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Is Eli Lilly Starting an Nvidia-Style Run? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
5 Best Growth Stocks for the Next 10 Years ↗
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors ↗
Via The Motley Fool
News headline image
The Smartest Growth Stocks to Buy With $2,000 Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Stock Split Watch: Is Eli Lilly Next? ↗
Via The Motley Fool
News headline image
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now ↗
Via The Motley Fool
News headline image
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗
Via MarketBeat
Topics Earnings
News headline image
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried? ↗
Via The Motley Fool
News headline image
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? ↗
Via The Motley Fool
Topics Government
News headline image
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗
Via The Motley Fool
News headline image
Don't Buy Viking Therapeutics Stock Until You Read This ↗
Via The Motley Fool
News headline image
Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗
Via The Motley Fool
News headline image
The Silver Lining of Last Week's Hims & Hers Earnings Miss ↗
Via MarketBeat
Topics Earnings
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Via FinancialNewsMedia
Topics Government

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 42.96
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 06/05/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story